DMP 266 non-nucleoside blocker of reverse transcriptase data

Data from an ongoing Phase II trial of DuPont Merck's DMP 266 combined with Merck's Crixivan show that 80 percent of 21

Read the full 222 word article

How to gain access

Continue reading with a
two-week free trial.